Login to Your Account



NYBA 21st Annual Meeting

Biopharmas' Commercialization Model is Slow to Evolve, Adapt

By Michael Harris
Senior Editor

Friday, May 4, 2012
NEW YORK – Revenue losses due to patent expirations, an increasingly complicated regulatory landscape and erratic results in getting drugs to market are key dynamics forcing biopharmas to take a look in the mirror and acknowledge the need for change, according to a panel at the New York Biotechnology Association 21st annual meeting this week.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription